App Store

Google Play

DK - Details page - Device banner - 894x1036

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

Lyt når som helst, hvor som helst 

Peter Attia

Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

The Peter Attia Drive

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this “Ask Me Anything” (AMA) episode, Peter revisits the topic of fasting, sharing how his thinking has evolved over time. The episode explores fasting-related terminology and common types of fasting, as well as the various reasons individuals might choose to fast. Peter explores potential benefits including improvements in body composition, metabolic health, lifespan extension, cardiovascular disease, cancer prevention and treatment, neurodegenerative conditions such as Alzheimer’s and Parkinson’s, and autoimmune symptoms like arthritis. He also examines the risks and potential downsides of fasting and offers a practical framework to help assess when and how fasting may be most appropriately applied.
 
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #72 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 
We discuss:
 
 • Why the topic of fasting is being revisited [1:45];
 • The importance of being open to changing one's opinion in science and medicine as new evidence emerges [4:15];
 • Defining fasting and how it fits in the framework of dietary restriction, time-restricted feeding, and calorie restriction [7:30];
 • The most common types of fasting [11:45];
 • Why someone might choose fasting over continuous caloric restriction [19:00];
 • The biochemical effects of fasting: fuel partitioning, autophagy, and more [21:00];
 • Autophagy: a cellular cleanup process stimulated by fasting and energy depletion [26:00];
 • Comparing the physiological effects of a ketogenic diet to those of long-term fasting [27:45];
 • How long fasting takes to induce ketosis and boost autophagy, and how autophagy is measured [29:45];
 • At-home tests for ketones [33:45];
 • Reducing senescent (“zombie”) cells and inflammation through autophagy [35:00];
 • Examining the evidence for the long-term health benefits of fasting beyond short-term metabolic effects [37:15];
 • The common health claims associated with fasting across metabolic, neurological, oncological, autoimmune, and longevity domains [40:30];
 • The impact of fasting on body weight and body composition [42:00];
 • Weight regain and potential metabolic consequences of fasting [44:00];
 • The risk of lean mass loss with fasting and how to mitigate it [47:15];
 A practical framework for using fasting as a strategy to improve body composition [52:15]; • How extended fasting compares to caloric restriction in improving insulin sensitivity in people with insulin resistance or type 2 diabetes [54:00];
 Is there any evidence that fasting can extend lifespan? [55:45]; • Examining whether fasting improves cardiovascular disease risk beyond the effects of weight loss and calorie reduction [58:15];
 • Exploring whether prolonged fasting can reduce cancer risk [59:45];
 • The potential benefits of fasting or fasting-mimicking diets during cancer treatment: emerging evidence and practical considerations [1:02:15];
 • Fasting for protection against neurodegenerative diseases: early evidence of therapeutic benefit and open questions [1:10:45];
 • Various fasting methods for autoimmune diseases: potential symptom relief with cautious application [1:14:00];
 • Fasting and type 1 diabetes: risks, evidence, and careful dietary alternatives [1:16:45];
 • Fasting and gut disorders: potential benefits outside of flare-ups [1:18:45];
 • The primary risks and downsides associated with fasting [1:19:45];
 • The essential vitamins and minerals to supplement during prolonged fasting [1:21:30];
 • Who should avoid fasting and why [1:22:15];
 • Fasting’s role in health: where it shows promise and where it likely offers no distinct advantage over caloric restriction [1:23:45]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#353 - AMA #72: Fasting: benefits for body composition and disease prevention, potential risks, and Peter’s updated practical framework

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this "Ask Me Anything" (AMA) episode, Peter delves into the realm of genetics, unraveling its connection to disease and emphasizing the value of understanding one's genetic risks. He elucidates essential background knowledge on genetics before delving into the myriad reasons why individuals might consider genetic testing. Peter differentiates scenarios where genetic testing provides genuine insights from those where it may not be as useful. From there, Peter explores a comprehensive comparison of commercial direct-to-consumer genetic tests, providing insights on interpreting results and identifying the standout options for gaining insights into personal health.
 
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #50 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 
We discuss:
 
 • Defining the term “genetics” and why it’s important [2:15];
 • What is DNA, and how does it impact our biology and traits? [5:45];
 • How are genetics passed down from parent to child? [8:45];
 • How much do genes vary across individuals? [13:00];
 • Which traits are determined by genetics versus experience or environmental factors? [17:00];
 • Reasons for genetic testing [22:30];
 • What exactly is being measured by a genetic test? [29:15];
 • Testing for monogenic disorders [35:15];
 • Understanding polygenic risk [39:30];
 • Is genetic testing more important for someone who doesn’t know their family history? [40:45];
 • What does it mean to be positive for a particular variant? [43:00];
 • What does it mean to be negative for a particular variant? [45:45];
 • How does someone get genetic testing through their healthcare provider, and how are these tests performed? [48:15];
 • The financial cost of various genetic tests [54:30];
 • Could having a risk allele for a disease result in an increase in one’s insurance premium? [57:15];
 • Other risks associated with genetic testing [59:00];
 • How do commercial, direct-to-consumer genetic tests compare to the information one might receive from clinical genetic testing? [1:01:45];
 • Are certain direct-to-consumer tests better than others? [1:03:45];
 • How long until whole genome sequencing becomes genuinely useful? [1:16:00];
 • How useful are personalized dietary recommendations based on genetics? [1:18:15];
 • Final thoughts and advice regarding genetic testing [1:20:00]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#266 - AMA #50: Genetics: how they impact disease risk, what you can do about it, testing, and more

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this "Ask Me Anything" (AMA) episode, Peter dives deep into one of the most frequently discussed and often misunderstood topics: nutrition. From weight loss and maintenance to the intricate relationship between nutrition and exercise and body composition, Peter addresses the complexities of nutrition research and explores the perennial question of whether there is a "best diet." He provides practical insights on how to choose the right diet for your unique needs, discusses the role of protein and processed foods, and outlines the key questions to help you optimize your approach to eating.
 
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #66 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 
We discuss:
 
 • The key nutrition-related topics to be discussed [1:30];
 • Why Peter is not fond of discussing nutrition: limitations of nutrition research, the pitfalls of extreme certainty in dietary discussions, and the body's adaptability to varied diets [3:30];
 • Key health metrics to monitor to evaluate the effects of nutrition [9:30];
 • The relationship between nutrition and exercise as they relate to weight loss, maintenance, and gain [12:30];
 • How increased muscle mass from resistance training impacts calorie burn, body composition, glucose metabolism, and overall health benefits [19:45];
 • Comparing the impact of fitness and nutrition on lifespan and healthspan: data showing fitness to be a more significant predictor of mortality than nutrition [23:30];
 • The myth of a “best diet,” factors that determine the effectiveness of a diet, and data suggesting benefits of the Mediterranean diet [39:00];
 • How long to trial a new diet, the importance of measurable goals, and the appropriate timescales for observing meaningful changes [48:30];
 • The inherent challenges in nutrition research: variability in dietary exposures, limitations in study design, the body’s adaptive nature which dampen the effects, and more [51:15];
 • Nutritional approaches for chronic diseases like cardiovascular disease and type 2 diabetes [58:45];
 • Emerging studies on dietary interventions for non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) [1:02:45];
 • Practical considerations for individuals to identify the best diet for them: protein intake, energy balance, macronutrient adjustments, and micronutrient levels [1:06:00];
 • Understanding processed vs. ultra-processed foods [1:09:15];
 • The effects of ultra-processed foods on health [1:12:30];
 • Questions that someone should ask themselves if they’re looking to fine-tune their diet [1:18:15]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#328 - AMA #66: Optimizing nutrition for health and longevity: myth of a “best” diet, complexities of nutrition science, and practical steps for building a sustainable diet

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this special episode of The Drive, Peter tackles a wide range of listener questions submitted over the past year. The discussion spans essential topics such as exercise—covering grip strength, traveling workouts, and why Peter doesn’t consider exercise an ideal weight-loss strategy—and the top biomarkers everyone should track. He also explores promising new longevity research, his evolving views on longevity, and frameworks like “objective, strategy, tactics” for personalized decision-making. The episode wraps up with insights on building good habits and a glimpse into Peter’s recent reading list.
 
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the Special AMA show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 
We discuss:
 
 • Overview of episode topics (and Peter’s car stereo saga) [1:45];
 • The importance of grip strength and the best methods for training it effectively [3:45];
 • Exercise while traveling: strategies for staying active and maintaining an exercise routine [14:45];
 • Why women should prioritize strength training [18:00];
 • The limited role of exercise in weight loss and its greater importance in improving health, body composition, and insulin sensitivity [19:45];
 • The “top five most important biomarkers” for assessing health [22:45];
 • Promising developments in longevity research [28:15];
 • The development of Klotho as a neuroprotective drug: challenges, timelines of trials, and more [34:00];
 • Peter’s updated view on the potential of epigenome manipulation to restore aged cells to their youthful state [39:45];
 • How reversing age-related epigenetic changes in immune cells could revolutionize our approach to aging and disease [43:30];
 • The “objective, strategy, tactics” framework, and the importance prioritizing impactful lifestyle habits over less significant health trends [49:30];
 • Strategies for building and maintaining good habits [56:45];
 • How to think about drugs and supplements as part of a longevity toolkit [1:02:00];
 • Peter’s recent reading list [1:05:15]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#329 ‒ Special AMA: Peter on exercise, important labs, building good habits, promising longevity research, and more

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
James Clear is the author of the New York Times bestseller Atomic Habits. His extensive research into human behavior has helped him identify key components of habit formation and develop the “Four Laws of Behavioral Change.” In this episode, James provides insights into how both good and bad habits are formed, including the influence of genetics, environment, social circles, and more. He points to changes one can make to cultivate more perseverance and discipline and describes the profound impact habits can have when tying them into one’s self-identity. Finally, James breaks down his “Four Laws of Behavioral Change” and how to use them to create new habits, undo bad habits, and make meaningful changes in one’s life.
 
We discuss:
 
 • Why James became deeply interested in habits [2:00];
 • Viewing habits through an evolutionary lens [6:15];
 • The power of immediate feedback for behavior change, and why we tend to repeat bad habits [9:30];
 • The role of genetics and innate predispositions in determining one’s work ethic and success in a given discipline [14:45];
 • How finding one’s passion can cultivate perseverance and discipline [23:30];
 • Advantages of creating systems and not just setting goals [29:30];
 • The power of habits combined with self-identity to induce change [36:45];
 • How a big environmental change or life event can bring on radical behavioral change [50:45];
 • The influence of one’s social environment on their habits [54:30];
 • How and why habits are formed [1:00:45];
 • How to make or break a habit with the “Four Laws of Behavior Change” [1:09:45];
 • Practical tips for successful behavioral change—the best strategies when starting out [1:16:30];
 • Self-forgiveness and getting back on track immediately after slipping up [1:30:45];
 • Law #1: Make it obvious—Strategies for identifying and creating cues to make and break habits [1:40:00];
 • Law #2: Make it attractive—examples of ways to make a new behavior more attractive [1:48:00];
 • Law #3: Make it easy—the 2-minute rule [1:59:00];
 • Law #4: Make it satisfying—rewards and reinforcement [2:03:45];
 • Advice for helping others to make behavioral changes [2:06:15]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

Building & Changing Habits | James Clear (#183 rebroadcast)

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
Trenna Sutcliffe is a developmental behavioral pediatrician and the founder and medical director of the Sutcliffe Clinic in the San Francisco Bay Area, where she partners with families to provide care for children facing behavioral challenges, developmental differences, and school struggles. In this episode, Trenna shares her journey into developmental and behavioral pediatrics, including her pioneering work at Stanford and her expertise in autism, ADHD, and anxiety—the "three As." She explores the diagnostic processes, the overlap and comorbidities of these conditions, and the importance of personalized treatment plans that address both medical and environmental factors. Trenna offers valuable insights into the changing prevalence of autism, the impact of evolving diagnostic criteria, and the range of therapies and medications available to support children and their families. She also discusses the challenges in accessing care and the critical need for a holistic approach that bridges healthcare and education.
 
We discuss:
 
 • Trenna’s passion for developmental-behavioral pediatrics (DBP), and the process of diagnosing anxiety, ADHD, and autism [3:15];
 • Understanding anxiety and ADHD: assessing impairment and self-esteem and identifying anxiety and emotional well-being in young patients [9:45];
 • The evolving diagnosis of autism: understanding the spectrum and individual needs [16:30];
 • The dramatic rise in autism spectrum disorder (ASD): genetics, environment, expanded diagnostic criteria, and more [25:45];
 • Exploring epigenetics and the potential multigenerational impact of environment exposures on susceptibility to certain disorders [37:15];
 • The evolution of autism classifications, and the particular challenges for children with level 1 (mild) autism due to a lack of support [41:15];
 • The broadening of the autism spectrum: benefits and risks of expanded diagnostic criteria and the need for future frameworks to focus on better outcomes [48:00];
 • The overlap between ASD, ADHD, and anxiety [57:15];
 • Understanding oppositional defiant disorder, and the importance of understanding the “why” behind a behavior when creating treatment plans [1:00:45];
 • Defining developmental-behavioral pediatrics (DBP), and Trenna’s professional journey [1:07:00];
 • Updated methods of ABA (applied behavioral analysis) therapy: evolution, controversies, challenges of scaling autism care, and the need for tailored interventions [1:13:45];
 • Advice for parents trying to find and evaluate care for children with autism, ADHD, or anxiety [1:22:45];
 Tailored treatments for ADHD: balancing stimulant medications with behavioral training [1:28:30]; • The interplay between medication, behavioral therapy, and neuroplasticity in managing ADHD, and the potential to grow out of the need for medication [1:39:45];
 • Using medication to treat anxiety and other symptoms in kids with autism without ADHD [1:44:45];
 • FAQs about medicating children with ADHD: benefits, side effects, dosage, and more [1:46:30];
 • The “superpowers” associated with level 1 autism [1:48:45];
 • The next steps to increase support for children with ASD, anxiety, and ADHD [1:50:45]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#330 – Autism, ADHD, and Anxiety: Understanding the rise in autism and a multidisciplinary approach to diagnosis and treatment of each condition in children | Trenna Sutcliffe, M.D.

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
Olav Aleksander Bu is an internationally renowned sports scientist acclaimed for his coaching prowess with elite athletes spanning a diverse range of sports disciplines. In this episode, Olav returns to dive deeper into his groundbreaking work as an endurance coach, exercise scientist, engineer, and physiologist. The discussion explores his data-driven approach to coaching, unpacking key performance metrics like functional threshold power, VO2 max, and lactate threshold, while emphasizing the importance of consistent testing protocols. Olav shares insights on how training methodologies differ across sports, the impact of nutrition on endurance performance, and the evolving strategies for carbohydrate metabolism in fueling athletes for races. Olav concludes with a discussion on the use of artificial intelligence for optimizing training insights and performance.
 
We discuss:
 
 • Olav’s unique, engineering-driven approach to endurance coaching [2:45];
 • Definitions and applications of key performance metrics: FTP, power, anaerobic threshold, and lactate threshold [4:45];
 • Lactate threshold: factors affecting lactate threshold, testing protocols, and how elite athletes' efficiency affects their performance and lactate profiles [14:15]
 • VO2 max: definition, testing, factors affecting its accuracy, and methods for optimizing oxygen utilization in elite athletes [22:15];
 • Testing VO2 max: common mistakes and key factors to consider—preparation, warm-up, timing, and more [34:00];
 • VO2 max testing continued: measuring instruments, testing protocols, and advanced insights gained from elite athletes [41:45];
 • The influence of supplements like beetroot concentrate and adaptogens on VO2 max and performance [49:45];
 • How respiratory quotient (RQ) reflects metabolic shifts during exercise, the challenges in measuring and interpreting RQ in elite athletes, and the physiological adaptations needed for prolonged endurance events [53:30];
 • Triathlon training: the challenge of maintaining elite performance across triathlon distances, metabolic efficiency, and swimming challenges [1:03:15];
 • How reducing drag in swimming could revolutionize performance and the role of biofeedback tools in optimizing efficiency across various endurance sports [1:07:00];
 • How endurance athletes prioritize effort regulation using RPE, heart rate, and power output, and the role of lactate in cardiac and athletic efficiency [1:20:00];
 • Lactate’s role as a fuel, buffering methods to combat lactic acidosis, and the variability in athlete response to bicarbonate supplementation [1:25:45];
 • The physiological mechanisms behind differences in performance between two elite athletes: lactate transport, cardiovascular efficiency, and compensatory systems [1:33:00];
 • Comparing interventions like acetaminophen to enhance performance in high-heat conditions versus natural adaptations to heat [1:37:15];
 • Advancements in nutrition science, changes in cyclist body composition, and the impact of fueling strategies on athletic performance and growth [1:39:30];
 • Optimizing endurance performance with utilization of carbohydrates, and the potential role of ketones [1:48:00];
 • Insights gained from elite performers in the 2020 and 2024 Olympics [1:58:30];
 • The use of artificial intelligence to optimizing training insights and performance [2:06:30]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#331 ‒ Optimizing endurance performance: metrics, nutrition, lactate, and more insights from elite performers | Olav Aleksander Bu (Pt. 2)

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this “Ask Me Anything” (AMA) episode, Peter tackles a topic that's been dominating headlines and sparking widespread concern: microplastics and plastic-associated chemicals, including BPA, PFAS, and phthalates. Peter explores the science behind these substances including how and why they've become so prevalent, the extent of our exposure, and the potential risks to our health. Most importantly, he provides a practical framework for understanding microplastics and plastic-associated chemicals and minimizing exposure while distinguishing genuine risks from exaggerated concerns.
 
If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #67 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
 
We discuss:
 
 • The complexity of the topic of microplastics and associated chemicals [1:30];
 • Definitions: microplastics, BPA, PM2.5, phthalates, and more [6:30];
 • The reasons behind the increase in microplastics in our environment and the surge in interest in them [12:00];
 • The various ways that humans are exposed to microplastics and nanoplastics [14:00];
 • Volume of plastic consumed by humans, and how the body eliminates or absorbs microplastics [16:00];
 • How microplastics accumulate in the body, the variability in tissue accumulation, and the challenges in studying their long-term health effects [21:30];
 • Limitations of blood tests for microplastics, and the importance of reliable biomarkers for guiding behavior and interventions [26:30];
 • The speculative health risks of microplastics, the limitations of current research, and the need for more robust studies [29:15];
 • The challenges of measuring microplastics in human tissues, the need for better methodologies, and the importance of critically evaluating study relevance and claims [39:45];
 • If it’s unclear whether microplastics actually cause harm, should we still be concerned about exposure? [42:15];
 • Strategies to minimize microplastic exposure [45:00];
 • The financial cost and effort involved in various microplastic exposure mitigation strategies [51:00];
 • The role of airborne microplastics in total exposure and accumulation [1:03:00];
 • Chemicals associated with plastics, their role as endocrine disruptors, and the challenges in linking exposure to specific health outcomes [1:04:00];
 • BPAs: role in plastic production, and its potential developmental risks [1:05:45];
 • BPA's potential health risks: pregnancy, fertility, obesity, and diabetes, and the socioeconomic confounders in the data [1:08:30];
 • Regulatory limits on BPA exposure, and practical considerations for reducing exposure [1:12:45];
 • The prevalence of BPA in modern products and how to identify it [1:17:15];
 PFAS: chemical structure and purpose in products [1:18:30]; • Why PFAS are considered endocrine disruptors [1:19:45];
 • The main sources of PFAS exposure, and practical steps to reduce exposure [1:21:30];
 • The potential health risks of PFAS exposure [1:24:00];
 • Phthalates: role in making plastics flexible and presence in personal care products [1:24:45];
 • Why phthalates are considered endocrine disruptors [1:25:15];
 • The main sources of phthalate exposure, and how manufacturing practices are evolving to reduce exposure [1:26:45];
 • Practical strategies to reduce exposure to phthalates in food, air, water, and personal care products [1:28:30];
 • Navigating microplastics and associated chemicals: a framework for personalized risk reduction [1:29:30]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#332 - AMA #67: Microplastics, PFAS, and phthalates: understanding health risks and a framework for minimizing exposure and mitigating risk

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
In this special episode of The Drive, Peter introduces a brand-new roundtable format. Joined by three renowned experts in longevity science—Steven Austad, Richard Miller, and Matt Kaeberlein—the group explores the rapidly evolving field of geroscience. Together, they dive deep into topics like the relationship between healthspan and lifespan, evaluating interventions like rapamycin and senolytics, the role of epigenetic changes in aging, and whether GLP-1 receptor agonists hold geroprotective potential. They also tackle major challenges in funding and public acceptance of longevity research including how geroprotective interventions might be tested in humans. Packed with nuanced debate, humor, and groundbreaking insights, this episode is a must-listen for anyone fascinated by the science of aging.
 
We discuss:
 
 • The recent rise in public interest in longevity, misconceptions, and the link between healthspan and lifespan [3:45];
 • Redefining healthspan, the US healthcare paradox, and separating longevity science from commercial hype [12:30];
 • The need to redirect medical research from disease-specific models to aging-focused approaches [21:30];
 • Proactive healthcare: rethinking health, disease, and the role of aging [30:00];
 • Biologic age versus chronologic age, and the limitations and potential of epigenetic clocks [35:00];
 • The utility and drawbacks of the “hallmarks of aging” as a framework for research and funding [49:30];
 • The role of epigenetic changes in aging and the challenges of proving causality [56:45];
 • The translational challenges of moving aging research from preclinical studies to human applications [1:03:45];
 • Distinguishing between a biomarker of aging and aging rate indicators [1:17:15];
 • The difficulties of translating longevity research in mice to humans, and the difficulties of testing interventions in humans [1:21:15];
 • Exercise, aging, and healthspan: does exercise slow aging? [1:35:45];
 • Are GLP-1 receptor agonists geroprotective beyond caloric restriction effects? [1:41:00];
 • The role of senescent cells in aging, challenges with reproducibility in studies, and differing views on the value of current research approaches [1:46:15];
 • How funding challenges and leadership in NIH and other institutes impact the advancement of aging-related research [2:00:15];
 • Metformin: geroprotective potential, mechanisms, and unanswered questions [2:02:30];
 • Canagliflozin and rapamycin as geroprotective molecules: mechanisms, dosing strategies, and longevity potential [2:10:45];
 • Resveratrol and NAD precursors—a lack of evidence for anti-aging effects [2:22:45];
 • The potential of parabiosis and plasmapheresis to slow aging, the challenges in translating mouse studies to humans, and possible design for human studies [2:29:45]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#333 ‒ Longevity roundtable — the science of aging, geroprotective molecules, lifestyle interventions, challenges in research, and more | Steven Austad, Matt Kaeberlein, Richard Miller

View the Show Notes Page for This Episode
 
 Become a Member to Receive Exclusive Content
 
 Sign Up to Receive Peter’s Weekly Newsletter
 
Tom Dayspring is a world-renowned expert in clinical lipidology and a previous guest on The Drive. In this episode, Tom explores the foundations of atherosclerosis and why atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide for both men and women. He examines how the disease develops from a pathological perspective and discusses key risk factors, including often-overlooked contributors such as insulin resistance and chronic kidney disease. He breaks down the complexities of cholesterol and lipoproteins—including LDL, VLDL, IDL, and HDL—with an in-depth discussion on the critical role of apolipoprotein B (apoB) in the development of atherosclerosis. Additionally, he covers the importance of testing various biomarkers, the impact of nutrition on lipid levels, and the vital role of cholesterol in brain health, including how cholesterol is synthesized and managed in the brain, how it differs from cholesterol regulation in the rest of the body, and how pharmacological interventions can influence brain cholesterol metabolism.
 
We discuss:
 
 • Defining atherosclerotic cardiovascular disease (ASCVD): development, risks, and physiological impact [2:45];
 • The pathogenesis of ASCVD: the silent development over decades, and the importance of early detection for prevention of adverse outcomes [10:45];
 • Risk factors versus risk markers for ASCVD, and how insulin resistance and chronic kidney disease contribute to atherosclerosis [17:30];
 • How hyperinsulinemia elevates cardiovascular risk [24:00];
 • How apoB-containing lipoproteins contribute to atherosclerosis, and why measuring apoB is a superior indicator of cardiovascular risk compared to LDL cholesterol [29:45];
 • The challenges of detecting early-stage atherosclerosis before calcification appears [46:15];
 Lp(a): structure, genetic basis, and significant risks associated with elevated Lp(a) [55:30]; • How aging and lifestyle factors contribute to rising apoB and LDL cholesterol levels, and the lifestyle changes that can lower it [59:45];
 • How elevated triglycerides, driven by insulin resistance, increase apoB particle concentration and promote atherosclerosis [1:08:00];
 • How LDL particle size, remnant lipoproteins, Lp(a), and non-HDL cholesterol contribute to cardiovascular risk beyond apoB levels [1:21:45];
 • The limitations of using HDL cholesterol as a marker for heart health [1:29:00];
 • The critical role of cholesterol in brain function and how the brain manages its cholesterol supply [1:36:30];
 • The impact of ApoE genotype on brain health and Alzheimer's disease risk [1:46:00];
 • How the brain manages cholesterol through specialized pathways, and biomarkers to track cholesterol health of the brain [1:50:30];
 • How statins might affect brain cholesterol synthesis and cognitive function, and alternative lipid-lowering strategies for high-risk individuals [1:57:30];
 • Exciting advancements in therapeutics, diagnostics, and biomarkers coming in the next few years [2:09:30];
 • Recent consensus statements on apoB and Lp(a) from the National Lipid Association (NLA) [2:12:30]; and
 • More.
 
Connect With Peter on Twitter, Instagram, Facebook and YouTube

#334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, cholesterol, brain health, and more | Tom Dayspring, M.D.

In this episode, Dr. Peter Hotez M.D., Ph.D., Dean for the National School of Tropical Medicine Baylor College of Medicine, returns to continue the conversation on COVID-19. Dr. Hotez informs us on how we can gauge the number of infected people, behaviors to reduce the probability of becoming infected, and the inconsistency of hospitalizations among young adults between different countries. Dr. Hotez underscores the continued uncertainty in many virus-related developments, but ends with some points of optimism.
 
 Disclaimer: This is information accurate as of March 19, 2020, when it was recorded.

 
We discuss:

 
 • 
 How to gauge true number of infected people [5:45]
 Reducing the probability of getting infected [22:45]
 Inconsistency by country in infected young people [27:15]
 Conferred immunity, seasonality, and repurposed therapeutics [30:30]
 Vaccine development [39:30]
 Practical behaviors to reduce risk of transmission [46:00]
 Mental Health resource and funding [51:00]
 Points of optimism [56:00]; and
 More.
 • 
 
Learn more: https://peterattiamd.com/
 
 Show notes page for this episode: https://peterattiamd.com/peterhotez-2
 
 Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
 
 Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
 
 Connect with Peter on Facebook | Twitter | Instagram.

#99 - Peter Hotez, M.D., Ph.D.: Continuing the conversation on COVID-19

Lyt når som helst, hvor som helst

Other podcasts you might like ...